|Day Low/High||0.11 / 0.16|
|52 Wk Low/High||0.07 / 0.71|
AIR001 Significantly Lowered Pulmonary Artery Pressures and Substantially Increased Pulmonary Arterial Compliance
Call Scheduled Tuesday, November 8, 2016 at 4:30pm ET / 1:30pm PT
Agreement Covers Ongoing and Future Clinical Studies of AIR001
Here's a technical look at how to trade some of the most active stocks on the market right now.
Conference call scheduled for September 21, 2016 at 8:00am ET
Sickle Cell Disease Coalition launches a call to action on neglected disease
Investors in Mast Therapeutics, Inc saw new options become available today, for the April 2017 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 242 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
Grant will support evaluation of vepoloxamer as an adjuvant agent to thrombolytic therapy for the treatment of acute stroke
Study conducted with support from a grant awarded by the National Heart, Lung, and Blood Institute, part of the National Institutes of Health
- Ex vivo study results indicate that by limiting unregulated calcium entry, vepoloxamer improves calcium cycling and left ventricle (LV) function in dogs with severe heart failure
- AIR001 significantly lowered pulmonary artery pressures
Very few people expect Mast's compound to become the first, new drug for sickle cell disease in almost 20 years. That's why Mast carries a miniscule $60 million market value.
Study to be conducted with support from a grant awarded by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH)
-Ex vivo study results indicate that by limiting unregulated calcium entry, vepoloxamer improves calcium cycling and left ventricle (LV) function in dogs with severe heart failure
Company anticipates top-line data in Q2 2016